HIRAYASU KAI

Dr. HIRAYASU KAI


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAKINARI SEKINE
AKINARI SEKINE
SHSumi Hidaka
Sumi Hidaka
TMTomofumi Moriyama
Tomofumi Moriyama
YSYasuto Shikida
Yasuto Shikida
KSKeiji Shimazu
Keiji Shimazu
SMSatoru Muto
Satoru Muto
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in which family history is unclear, a differential diagnosis between ADPKD and other cystic kidney diseases is important. When diagnosing ADPKD, cystic kidney diseases that can easily be excluded using clinical information include: multiple simple renal cysts, acquired cystic kidney disease (ACKD), multilocular renal cyst/multilocular cystic nephroma/polycystic nephroma, multicystic kidney/multicystic dysplastic kidney (MCDK), and unilateral renal cystic disease (URCD). However, there are other cystic kidney diseases that usually require genetic testing, or another means of supplementing clinical information to enable a differential diagnosis of ADPKD. These include autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant tubulointerstitial kidney disease (ADTKD), nephronophthisis (NPH), oral-facial-digital (OFD) syndrome type 1, and neoplastic cystic kidney disease, such as tuberous sclerosis (TSC) and Von Hippel-Lindau (VHL) syndrome. To help physicians evaluate cystic kidney diseases, this article provides a review of cystic kidney diseases for which a differential diagnosis is required for ADPKD.

21 March 2024 in Kidney360
Verified
Journal Article
Open access
RIRyota Ishii
Ryota Ishii
HKHIRAYASU KAI
HIRAYASU KAI
KNKentaro Nakajima
Kentaro Nakajima
THTakuya Harada
Takuya Harada
TATomoki Akiyama
Tomoki Akiyama
KYKunihiro Yamagata
Kunihiro Yamagata
Key Points: The mechanism of decreased renal function in autosomal dominant polycystic kidney disease has not been elucidated yet. The presented data highlight specific renal hemodynamic changes that occur in patients with autosomal dominant polycystic kidney disease. Background: Although the mechanisms underlying cyst enlargement in autosomal dominant polycystic kidney disease (ADPKD) are becoming clearer, those of renal dysfunction are not fully understood. In particular, total kidney volume and renal function do not always correspond. To elucidate this discrepancy, we studied in detail glomerular hemodynamic changes during ADPKD progression. Methods: Sixty-one patients with ADPKD with baseline height-adjusted total kidney volume (Ht-TKV) of 933±537 ml/m and serum creatinine of 1.16±0.62 mg/dl were followed for 2 years. GFR and renal plasma flow (RPF) slopes were calculated from inulin clearance (Cin) and para-aminohippuric acid clearance (CPAH), respectively, while glomerular hydrostatic pressure (Pglo), afferent resistance (RA), and efferent resistance (RE) were estimated using the Gomez formulas. Each parameter was compared with baseline Ht-TKV. Patients were also subclassified into 1A–1B and 1C–1E groups according to the baseline Mayo imaging classification and then compared with respect to GFR, RPF, filtration fraction, and glomerular hemodynamics. Results: After 2 years, Ht-TKV increased (933±537 to 1000±648 ml/m, P < 0.01), GFR decreased (66.7±30 to 57.3±30.1 ml/min per 1.73 m2, P < 0.001), and RPF decreased (390±215 to 339±190 ml/min per 1.73 m2, P < 0.05). Furthermore, Pglo was decreased and RA was increased. Baseline Ht-TKV was inversely correlated with GFR (r=−0.29, P < 0.05), but there was no association between baseline Ht-TKV and RPF, Pglo, RA, or RE annual changes. However, despite an increase in RE in the 1A–1B group, RE was decreased in the 1C–1E group. As a result, RE slope was significantly lower in the 1C–1E group than the 1A–1B group over time (−83 [−309 to 102] to 164 [−34 to 343] dyne·s·cm−5, P < 0.01). Conclusions: This is the first report examining yearly changes of GFR (inulin), RPF (para-aminohippuric), and renal microcirculation parameters in patients with ADPKD. Our results demonstrate that GFR reduction was caused by RA increase, which was faster because of RE decrease in patients with faster Ht-TKV increase.

1 April 2009 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
KSKentaro Sakai
Kentaro Sakai
JUJoichi Usui
Joichi Usui
HKHIRAYASU KAI
HIRAYASU KAI
MHMasahiro Hagiwara
Masahiro Hagiwara
NMNaoki Morito
Naoki Morito
KYKunihiro Yamagata
Kunihiro Yamagata

1 March 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HKHIRAYASU KAI
HIRAYASU KAI
JUJoichi Usui
Joichi Usui
TTTakashi Tawara
Takashi Tawara
MTMayumi Takahashi-Kobayashi
Mayumi Takahashi-Kobayashi
RIRyota Ishii
Ryota Ishii
KYKunihiro Yamagata
Kunihiro Yamagata
A 28-year-old woman was admitted during the eighth week of her pregnancy because her clinical course was consistent with rapid progressive glomerulonephritis (RPGN). Anti-glomerular basement membrane antibody (anti-GBM Ab) and MPO-ANCA were positive, and the anti-GBM Ab titer being extremely high. She was treated with hemodialysis, plasma exchange and prednisolone. She survived the illness; however, neither the fetus nor her kidney function could be rescued. She had HLA-DRB1*1502:01, which differs from the DRB1*1501 associated with anti-GBM GN. When patients have particular symptoms, we should check the urine and serum creatinine to exclude RPGN, even in cases of pregnancy.

15 March 2026 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TMTeppei Motomura
Teppei Motomura
MHMayuka Higashi
Mayuka Higashi
AHAkihisa Hattori
Akihisa Hattori
RARyosuke Akiyama
Ryosuke Akiyama
HKHIRAYASU KAI
HIRAYASU KAI
Objective Hyperuricemia is associated with cardiovascular disease and chronic kidney disease (CKD). Dotinurad is a new uricosuric drug that has not been evaluated in clinical trials in patients with advanced CKD (CKD G3b-G5). This study evaluated the efficacy of dotinurad in lowering serum uric acid levels, its safety profile, and its effect on the renal function in hyperuricemic patients with CKD G3b to G5. Methods This was a single-center retrospective observational study. Patients and Materials Fourteen patients with CKD G3b to G5 who received dotinurad in the outpatient clinic and for whom data were available for six months before and after treatment were enrolled in this study. Serum uric acid levels six months after treatment and the estimated glomerular filtration rate (eGFR) six months before and after treatment were evaluated. Results Serum uric acid levels significantly decreased from 8.2 (8.0-8.5) mg/dL to 6.2 (5.9-7.2) mg/dL six months after treatment (p<0.01). The eGFR was 25.4 (19.4-40.6) mL/min/1.73 m2 6 months before treatment and 24.9 (18.3-35.5) mL/min/1.73 m2 at the time of treatment, but 24.4 (19.2-36.4) mL/min/1.73 m2 at 6 months after treatment, with no significant change noted. No adverse events were observed. Conclusion Dotinurad can safely lower serum uric acid levels in hyperuricemic patients with advanced CKD.

17 November 2015 in CEN Case Reports
Verified
Journal Article
Open access
PDF file
HKHIRAYASU KAI
HIRAYASU KAI
YSYuki Shinozaki
Yuki Shinozaki
ANAiri Nishikubo
Airi Nishikubo
MWMegumi Watanabe
Megumi Watanabe
TTTakashi Tawara
Takashi Tawara
KYKunihiro Yamagata
Kunihiro Yamagata
We report here two cases of autosomal dominant polycystic kidney disease (ADPKD) with renal dysfunction that were treated with tolvaptan. Case 1 was a 47-year-old man with a glomerular filtration rate (GFR) of 17.0 ml/min/1.73 m2 who received tolvaptan treatment (30 mg/day). After treatment, kidney pain was alleviated, and the estimated GFR (eGFR) decline improved from −9.84 ml/min/1.73 m2 per year to −4.08 ml/min/1.73 m2 per year, respectively. The rate of increase in total kidney volume was reduced from 18 % per year before treatment to 4 % per year following tolvaptan administration. Case 2 was a 44-year-old man with a GFR of 22.6 ml/min/1.73 m2, and the eGFR decline improved from −5.76 ml/min/1.73 m2 per year before treatment to −3.12 ml/min/1.73 m2 per year following tolvaptan treatment (30 mg/day). The rate of increase in total kidney volume was also decreased from 10 % per year before treatment to −7 % per year following tolvaptan administration. These results suggested that tolvaptan may be effective in impeding kidney function aggravation and kidney volume increase in ADPKD patients with advanced renal dysfunction.